In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Aventis Antes Up in Antibodies

Executive Summary

Aventis SA's oncology franchise is anchored by the blockbuster Taxotere. Sales of the drug comprise more than 8% of Aventis's core pharma business, and are currently growing more than 25% worldwide and in the US. Yet until recently, the firm had few other products with which to leverage its commercial infrastructure in oncology. It is therefore teaming up with ImmunoGen Inc. to create antibody-based oncology therapeutics using drug targets provided by both companies.
Table

View full table

Advertisement
Advertisement

Related Content

In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

IV002172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By